title: Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate.
authors.affiliation: Dept of Atherosclerosis, INSERM U 325, Institut Pasteur de Lille, France.
authors.forename: L
authors.initials: L
authors.lastname: Beghin
authors.forename: N
authors.initials: N
authors.lastname: Capps
authors.forename: N
authors.initials: N
authors.lastname: Duhal
authors.forename: J
authors.initials: J
authors.lastname: Davies
authors.forename: B
authors.initials: B
authors.lastname: Staels
authors.forename: G
authors.initials: G
authors.lastname: Luc
mesh_terms: D016632:Apolipoprotein A-I / Q000097:blood*; D016633:Apolipoprotein A-II / Q000097:blood*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058607:Fibric Acids; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008875:Middle Aged
chemical_list: D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D058607:Fibric Acids; D008075:Lipoproteins, HDL; D002995:Clofibric Acid; C019304:ciprofibrate